ZEB2 and pachyonychia congenita: ZEB2, in turn, demonstrated opposite profiles with the progression of PC, as it was upregulated in patients below 55 years old in contrast to the groups of 60–70 and above 70 years old at the early stage, but, at the late stage, the expression dropped in the former and heightened in the latter groups.